NeuroSense Therapeutics has taken a significant step toward bringing its experimental ALS treatment PrimeC to the Canadian market after receiving an invitation from Health Canada for a pre-New Drug Submission meeting. The company aims to secure a Notice of Compliance with conditions (NOC/c) for the drug, potentially enabling early market entry by the first half of 2026.
PrimeC, a novel oral combination therapy using ciprofloxacin and celecoxib, has shown promising clinical results. In its Phase 2b PARADIGM study, the drug demonstrated a 36% reduction in disease progression and a 43% improvement in survival rates compared to placebo, offering hope for ALS patients facing limited treatment options.
The regulatory pathway comes alongside NeuroSense's broader global development strategy. In December 2024, the company received positive FDA feedback on its Phase 3 trial design, with plans to initiate the pivotal study in mid-2025. Additionally, NeuroSense has entered a binding term sheet with a global pharmaceutical partner, securing substantial upfront payments and funding for the Phase 3 program.
The potential commercialization of PrimeC aligns with recent trends in the neurodegenerative treatment market, where pharmaceutical companies have shown willingness to invest heavily in innovative neurological therapies. Comparable deals, such as GlaxoSmithKline's 2021 collaboration with Alector and Biogen's partnership with Denali Therapeutics, demonstrate the significant value placed on breakthrough treatments.
With estimated peak annual revenue potential of $100-150 million in the Canadian market alone, PrimeC represents a significant opportunity for NeuroSense. The company's strategic approach of pursuing conditional approval while simultaneously advancing global clinical trials could accelerate patient access to a potentially transformative ALS treatment.
